Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a phone app stop suicide? new trial aims to find out

NCT ID NCT07160465

Symptom relief Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether a smartphone app called emma, used alongside the standard VigilanS program, can reduce suicide events (like attempts or hospital visits) in adults who recently attempted suicide. The app lets users quickly contact crisis support, tracks mood, and offers coping tools. Researchers will follow 632 participants for 6 months to see if the app makes a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
emma smartphone application
What this could lead to
If it works, this app could provide real-time support and risk detection for people at high risk of suicide, potentially reducing suicide attempts and deaths.
What could go wrong
This is an early-stage trial with no prior efficacy data. The app relies on self-reporting and smartphone access, which may not suit everyone. Results may not generalize beyond the French healthcare system.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 632 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject aged 18 or over * Subject benefiting from the VigilanS program (after an admission to an emergency ward following a suicide attempt) * Subject with his own smartphone (iOS/Androïd) * Subject able to understand the nature, purpose and methodology of the study * Subject must be covered by public health insurance * Signed informed consent form Exclusion Criteria: * Subject unable to read or/and write French * Planned longer stay outside the region that prevents compliance with the visit plan * Being protected by the law (tutorship or curatorship) * Being deprived of liberty by administrative decision * Being in a period of exclusion compared to another protocol * Pregnant and breastfeeding women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Suicide are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Suicide Suicide, Attempted

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Suicide Suicide attempt

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University hospital

    Montpellier, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.